The US Patent and Trademark Office grants Brighter's patent for a safety mechanism when combining injection functionality which is regulated under MDD ("Medical Device Directive") and diagnostic technology which is regulated under IVDD ("In-Vitro Diagnostics Directive") into one unit. The patent is an extension of Brighter's main patent. The company thereby strengthens its protection for combination solutions and the collection of unique valid treatment data in the US, one of the largest markets for Actiste Diabetes Management as a Service, which is the Brighter's first application based on the patent. The unit brings together and combine all the necessary functions for diabetes care - blood sampling, blood glucose measurement and drug injection - in a single connected device. The solution is based on patented technology for collecting data on specified biomarkers and injected volumes of drugs. With state-of-the-art eSIM technology, Actiste has global out-of-the-box connectivity, which means that it is completely independent of other devices for sharing health and treatment data. Actiste received two CE-marks in September 2019 - one for MDD and one for IVDD. The Actiste device is delivered as part of a subscription service. The service includes global connectivity, different levels of data sharing, continuous and automatic replenishment of consumables, and enables coaching and guidance to optimize and improve treatment.